EAM
ATOS icon

Evanson Asset Management’s Atossa Therapeutics ATOS Stock Holding History

Evanson Asset Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-667
Closed -$8.3K – 326
2025
Q2 		$8.3K Hold
667
– – ﹤0.01% 325
2025
Q1 		$6.73K Hold
667
– – ﹤0.01% 307
2024
Q4 		$9.44K Hold
667
– – ﹤0.01% 307
2024
Q3 		$15.2K Hold
667
– – ﹤0.01% 304
2024
Q2 		$11.9K Buy
+667
New +$14.8K ﹤0.01% 298

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Evanson Asset Management's ATOS Position: Q3 2025 in Review

Evanson Asset Management sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 667 shares — an estimated $8.3K sold.

Evanson Asset Management first reported a position in ATOS in Q2 2024 and held it in 5 quarters. The position peaked at $15.2K in Q3 2024. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Evanson Asset Management reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Evanson Asset Management sold 667 Atossa Therapeutics shares in Q3 2025, an estimated $8.3K.
  • Evanson Asset Management first reported a position in Atossa Therapeutics in Q2 2024 and held it in 5 quarters.
  • Evanson Asset Management's Atossa Therapeutics position peaked at $15.2K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Evanson Asset Management's 13F filing for Q3 2025, filed 14 Oct 2025.